Intercept Downgraded To Sell From Neutral At H.C. Wainwright

clear flask tubes lot

Source: Unsplash 

H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals (ICPT) to Sell from Neutral with a price target of $25, down from $46, after the company disclosed that its Chief Medical Officer Jason Campagna has decided to resign effective March 5.

Campagna's two-week notice "represents the clearest sign yet that the long-term future of Ocaliva is in serious doubt," Arce tells investors in a research note.

The analyst believes the ongoing feedback from the FDA, since the Type A end-of-review meeting last year and in more recent communications since likely points to a "difficult road ahead" for any potential resubmission of the application for Ocaliva in nonalcoholic steatohepatitis.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Mike Faragut 4 days ago Member's comment

Does this matter? They upgraded one of my stocks last week $ABEO to a price that is 3 times the price then and it went down so hard since then. Screw the Anal-ysts.